REMSLEEP HOLDINGS INC - RMSL STOCK NEWS

REMSleep Holdings, Inc. (OTCQB: RMSL) has received approval for another utility patent for its Nasal Ventilation System from the United States Patent and Trademark Office. The company expects to be awarded the patent in about 8 weeks after filing the necessary paperwork. REMSleep is awaiting silicone raw materials, expected to arrive in early October, to begin production of the Deltawave CPAP pillows interface.

Following the Deltawave launch, REMSleep plans to submit a 510K application for its next-generation product, 'Longevity', with an expected clearance time of approximately 5 months. The company also anticipates launching a third-generation CPAP interface mask by the end of 2025. REMSleep projects significant growth, expecting to become a substantial company by the end of 2025.

REMSleep Holdings Inc. (OTCQB: RMSL) has announced its goal to capture 10% of the CPAP mask market within 24 months. The company recently received FDA approval for its DELTAWAVE Nasal Pillows System, which aims to address the high non-compliance rate in CPAP therapy users. REMSleep is focusing on the 36% of users who abandon CPAP therapy due to mask discomfort.

The company plans to intensify sales and marketing efforts, build relationships with key distributors, and educate medical professionals about their product's benefits. REMSleep also intends to conduct FDA clinical trials to confirm the effectiveness of their masks in alleviating COPD and CHF symptoms, potentially opening a new market. Their ultimate goal is to graduate to Nasdaq within the next 24 months.

REMSleep Holdings, Inc. (OTCQB: RMSL) has announced that a major CPAP industry distributor has requested samples of its new DELTAWAVE Nasal Pillows System. This development marks a significant milestone for REMSleep in its mission to revolutionize sleep apnea treatment. The company is currently preparing samples for shipment, highlighting the product's design for enhanced user comfort and effectiveness.

CEO Tom Wood expressed enthusiasm about the potential impact, viewing it as an opportunity to showcase their innovative product to a leading distributor. REMSleep anticipates that this could lead to broader distribution opportunities. The company remains committed to keeping shareholders informed about progress in advancing sleep apnea treatment solutions.

REMSleep Holdings Inc. (OTCQB: RMSL) has announced a strategic marketing plan for its DELTAWAVE Nasal Pillows System, a revolutionary sleep apnea treatment solution. The company aims to expand market presence by partnering with key distributors nationwide. The plan includes:

• Identifying top-tier distributors
• Providing comprehensive training programs
• Expanding market reach
• Launching marketing and awareness campaigns

CEO Tom Wood emphasized the company's commitment to sustainable growth and long-term success, focusing on advancing technology and improving lives of individuals affected by sleep apnea. REMSleep Holdings Inc. is confident in DELTAWAVE's potential to become a leading solution in the market.

REMSleep Holdings announced that it received 510(K) clearance for its new Deltawave CPAP Pillows Interface mask. The clearance allows the device to be marketed under the regulations set by the FDA. This product is classified as a Class II noncontinuous ventilator and meets the necessary regulatory requirements. With this approval, REMSleep plans to prepare the Deltawave CPAP interface for market launch by updating its website, ordering inventory, and corresponding with distributors. The company also identified notable short interest and possible illegal naked short sales, committing to legal actions to protect shareholder interests.

REMSleep Holdings, Inc. (RMSL) receives a new patent for Sleep Apnea Cannula and Nasal Pillows Device, with a 15-year expiration. The Firm advises marking products with the patent number U.S. Pat. No. D1017025.

REMSleep Holdings, Inc. (RMSL) provides an update on FDA process and REMSleep status. The company is undergoing shelf-life testing and awaiting results to resubmit its 510(K) application. REMSleep aims to improve CPAP machine comfort and compliance for individuals with severe obstructive sleep apnea (OSA) or OSA complicated by congestive heart failure (CHF).

RemSleep Holdings Inc. (RMSL) has received a response regarding the 510(K) submission for their medical device dedicated to treating Obstructive Sleep Apnea (OSA). The FDA has requested additional information and testing related to Administrative Information, Device Description, Substantial Equivalence, Labeling, Biocompatibility, and Performance testing. The company is in the process of providing the required answers and tests. The CEO has assured investors of their commitment to gaining approval for the submission as soon as possible. The company has also applied for a government grant for clinical trials and has been granted a new US patent for their product(s).

RemSleep Holdings Inc. announces that its DeltaWave mask has moved to the Substantive Review portion of the FDA 510k review process. The company voluntarily withdrew its 510k submission during the Acceptance Review portion but made changes to address reviewer comments. The current FDA reviewer is the same individual who was assigned to the previous submission. The company is confident in the comprehensive testing regimen and expects the DeltaWave to be safe. Discussions with interested distributors have resumed. RemSleep will provide updates on its website and Twitter feed.